MR-guidance in Chemoradiotherapy for Cervical Cancer

Concurrent chemoradiotherapy (CCRT), consisting of external beam radiotherapy (EBRT) and chemotherapy, followed by brachytherapy (BT) is the standard of care for patients with locally advanced cervical carcinoma. In current clinical practice, conventionally, one radiotherapy plan based on the initial planning computed tomography (CT) and magnetic resonance imaging (MRI) scan of the pelvis is applied for the complete 5-6 weeks of EBRT. However, there is a high degree of cervix and uterus motion in the pelvis due to different fillings of the bladder and the bowel. Consequently, large safety marg

Trial Details

NCT ID
NCT06142760
Phase
NA
Sponsor
Juergen Debus
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • MR-guided radiation
Locations (sample)
  • Heidelberg, Germany|49.40768,8.69079

Key Eligibility Criteria

  • biopsy-proven cervical cancer including squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma
  • FIGO stage IB, IIA, IIB, IIIA, IIIB, IIIC1
  • indication and eligibility for definitive chemoradiotherapy including brachytherapy discussed in an interdisciplinary tumor board
  • Karnofsky performance score ≥ 70%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →